Although this effect is not widely recognized, testosterone therapy can interact with thrombophilia, causing osteonecrosis. In 12 men and 4 women who had idiopathic osteonecrosis a median of 6 months after the onset of testosterone therapy, the authors examined the interaction between testosterone therapy and previously undiagnosed thrombophilia. The authors hypothesized that patients who had osteonecrosis after starting testosterone therapy were more likely than 110 normal control subjects or 48 patients who had osteonecrosis and were not receiving testosterone therapy to have thrombophilia. Measures of thrombophilia included Factor V Leiden, prothrombin, PAI-1 gene mutations, Factor VIII, Factor XI, anticardiolipin antibody immunoglobulin G or immunoglobulin M, and homocysteine values. In 10 cases, osteonecrosis occurred 6 months or less after the onset of testosterone therapy, and in all 16 cases, it occurred after a median of 6 months of testosterone therapy. Of the 16 cases, 5 (31%) were Factor V Leiden heterozygotes vs 2 of 109 (2%) healthy control subjects (P=.0003) and 4 of 48 patients who had osteonecrosis and were not receiving testosterone therapy (P=.04). Of the 16 cases, 4 (25%) had high (>150%) Factor VIII levels vs 7 of 103 (7%) healthy control subjects (P=.04), and 3 (19%) had high (>150%) Factor XI levels vs 3 of 101 (3%) healthy control subjects (P=.03). Of the 16 patients with osteonecrosis, 14 (88%) had at least 1 abnormal procoagulant value (of the 8 measured) vs 47 of 110 (43%) healthy control subjects (P=.0009). Of the 5 men whose serum estradiol level was measured while they were receiving testosterone therapy, this level was high (≥42.6 pg/mL) in 4. When testosterone therapy is given to patients with thrombophilia, they are at increased risk for osteonecrosis. [Orthopedics. 2015; 38(12):e1073-e1078.] The authors are
I diopathic osteonecrosis, defined by as osteonecrosis that is not secondary to excess use of alcohol, long-term use of high-dose corticosteroids, hip fracture or dislocation, or similar causes, is often caused by familial and acquired thrombophilia. [1] [2] [3] [4] [5] The authors posited that osseous venous thrombosis, facilitated by thrombophilia, leads to increased intraosseous venous pressure, reduced intraosseous arterial flow, hypoxia, bone death, and osteonecrosis. 4, 6, 7 This pathophysiologic sequence is important to understand because short-term (3 months) 8 or long-term (years) 4 treatment with anticoagulation has been shown to stop the progression of osteonecrosis if there has been no joint collapse (Ficat stage I or II).
The authors recently showed that when exogenous testosterone is given to men or women with previously undiagnosed familial and acquired thrombophilia, thrombosis can occur, usually within a median of 4 to 6 months after the initiation of testosterone therapy. 9, 10 Previously, the authors 9-14 described thrombotic events that occurred after a median of 5 months of testosterone therapy in 42 patients, 38 men and 4 women, including 27 with deep venous thrombosis or pulmonary embolism, 12 with osteonecrosis, 9 1 with central retinal vein occlusion, 1 with amaurosis fugax, and 1 with spinal cord infarction. Of the 42 cases in the authors' previous studies, [9] [10] [11] [12] [13] [14] no patient had elevated hemoglobin or uncontrolled hypertension during testosterone therapy that might have contributed to thrombosis. Of the 42 cases, 40 had measures of thrombophilia and hypofibrinolysis, and 39 had previously undiagnosed thrombophilia and hypofibrinolysis, including, most commonly, 28% who were heterozygous for the Factor V Leiden mutation, 28% with a high Factor VIII level, and 15% with a high Factor XI level. 9 Second thrombotic events occurred in all 8 men whose testosterone therapy was continued, despite adequate anticoagulation with warfarin. 9 The physiologic hyperestrogenemia of pregnancy or exogenous estrogen 15 can promote the development of osteonecrosis. [16] [17] [18] The authors have shown that, parallel to the action of estrogens in promoting thrombosis in subjects with underlying prothrombotic mutations, 19 exogenous testosterone, particularly when given to older obese men, can lead to a high level of serum estradiol, 13 speculatively interacting with the underlying thrombophilia to produce thrombosis.
In the current study of 16 patients (12 men, 4 women) who were not previously known to have thrombophilia, the authors assessed the interaction between testosterone therapy and familial and acquired thrombophilia that led to the development of osteonecrosis a median of 6 months after initiation of testosterone therapy. The authors hypothesized that patients who had osteonecrosis after the onset of testosterone therapy were more likely to have thrombophilia than 110 normal control subjects, 55 men who received testosterone therapy but did not have osteonecrosis (testosterone therapy control subjects), and 48 age-and sexmatched control subjects who had osteonecrosis but were not receiving testosterone therapy. The authors also examined how often men receiving testosterone therapy had thrombophilic high levels of estradiol.
Materials and Methods

Informed Consent
The study followed a protocol approved by the authors' institutional review board, and signed informed consent was obtained from all participants.
Cases
The sole inclusion criterion was the development of osteonecrosis after the initiation of testosterone therapy. Over a 4-year period, 16 cases were referred to the authors and were studied in the sequential order of their referral, without any exclusion criteria.
Control Subjects
The authors studied 110 healthy normal control subjects (48 men, 62 women), without osteonecrosis who were recruited from healthy hospital personnel. In addition, the authors studied 55 male control subjects (testosterone therapy control subjects) who received testosterone therapy but did not have osteonecrosis, deep venous thrombosis, or pulmonary emboli. The authors also studied 48 patient control subjects who had osteonecrosis but were not receiving testosterone therapy, matched 3:1 to the 16 cases by age and sex, to assess the increased risk of osteonecrosis conferred by concurrent testosterone therapy and familial and acquired thrombophilia.
Laboratory Assessment of Thrombophilia
Polymerase chain reaction measures of thrombophilia (G1691A Factor V Leiden, G20210A prothrombin) and hypofibrinolysis (PAI 4G4G) were performed in all cases and control subjects using previously published methods by laboratory staff blinded to the participants' status (diagnosis, severity of disease). 20 Serologic measures of thrombophilia included Factors VIII and XI, homocysteine, and anticardiolipin antibodies immunoglobulin G and immunoglobulin M. Established, previously published methods were used. 6 The components of the antiphospholipid antibody syndrome were measured by enzyme-linked immunosorbent assay, according to previously published methods.
Measures of Testosterone and Estradiol
Levels of total testosterone, estradiol, and free estradiol were measured in a single laboratory (LabCorp, Dublin, Ohio). Total testosterone and estradiol levels were measured with electrochemiluminescence immunoassay. 21 A high homocysteine level was defined as greater than the 95th percentile 22 for control subjects.
Statistical Analysis
All statistical analyses were done with SAS version 9.4 software (SAS Institute Inc, Cary, North Carolina).
Wilcoxon nonparametric tests were used for comparisons of continuous variables. For categorical variables, Fisher's exact test was used.
results
Osteonecrosis was idiopathic in all 16 cases. These patients had not taken high-dose, long-term corticosteroids, did not abuse alcohol, and did not have a hip fracture or dislocation. As shown in Table 1 , osteonecrosis was present in the hips in 11 patients (21 hips), was present in the knees in 3 patients (4 knees), and was multifocal in 2 patients. Mean (±SD) and median age were 53±10 years and 54 years, respectively. The study group included 12 men and 4 women; the women had taken testosterone therapy for libido enhancement and the men had taken it because of hypogonadism.
In 10 of the 16 cases, osteonecrosis occurred 6 months or less after the initiation of testosterone therapy, and in all 16 cases, it developed after a median of 6 months ( Table 1) .
Cases differed from normal control subjects in sex (75% men vs 44% men, P=.03) and age (median, 54 years vs 44 years; P=.002), but not by body mass index (median, 26.3 vs 25.6 kg/m 2 ). Of the 16 cases, 5 (31%) were Factor V Leiden heterozygotes vs 2 of 109 healthy control subjects (P=.0003) ( Table 2) . Of the 16 cases, 4 (25%) had high (>150%) Factor VIII levels vs 7 of 103 (7%) healthy control subjects (P=.04). In addition, 3 of the 16 cases (19%) had high (>150%) Factor XI levels vs 3 of 101 (3%) healthy control subjects (P=.03) ( Table 2) .
Factor V Leiden heterozygosity was more common in the 16 cases than in the 55 testosterone therapy control subjects (31% vs 3%; 1/40; P=.006) ( Table 2) .
Factor V Leiden heterozygosity was more common in the 16 cases than in the 48 age-and sex-matched control subjects who had osteonecrosis and were not receiving testosterone therapy (31% vs 8%; 4/48; P=.04) ( Table 2) .
The total number of abnormal values for 8 measured coagulants (Factor V Leiden, prothrombin G20210A, PAI-1, Factor VIII, Factor XI, anticardiolipin antibody immunoglobulin G and immunoglobulin M, and homocysteine) was calculated for each of the 16 cases and 110 normal control subjects. Abnormal values for 1 or more procoagulants were found in 14 of the 16 patients (88%) with osteonecrosis vs 47 of 110 (43%) healthy control subjects (P=.0009) ( Table 2) .
Of the 5 patients in whom serum estradiol was measured while receiving testosterone therapy, this level was high (≥42.6 pg/mL) in 4.
discussion
The current authors 4, 8, 23 and others 3,24-30 focused on thrombophilia as an important and treatable 4, 7, 8 pathoetiology of osteonecrosis of the hip and knee, provided that the bone has not collapsed. The authors previously reported that when 
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Copyright © SLACK inCorporAted n Feature Article Although it is not conventionally included in the family of thrombotic events associated with thrombophilia (deep venous thrombosis, venous thrombotic event, pulmonary embolism, central retinal vein and artery occlusion), many of which can be treated successfully with anticoagulation, the authors believe that osteonecrosis is a member of this family. 4, [6] [7] [8] 31 Further, they believe that, provided that the osteonecrotic bone has not collapsed, osteonecrosis can also be treated successfully with anticoagulation. 4, 7, 8 Within this frame of reference, a previous venous thrombotic event and/or the development of osteonecrosis 6 months after starting testosterone therapy should alert the physician to the likelihood of an underlying familial or acquired thrombophilia. Moreover, in all 8 cases when testosterone therapy was continued after an initial venous thrombotic event, second and third thrombotic events occurred, despite adequate anticoagulation. 9 In this frame of reference, when osteonecrosis develops after the initiation of testosterone therapy, this therapy should be immediately and permanently stopped. 9 Thrombophilia in the general healthy public reflects a target-rich environment. 28, [32] [33] [34] [35] When hormonal bullets (testosterone or estradiol) are fired, many targets will be hit, with resultant thrombotic events, including osteonecrosis. Increased risk of osteonecrosis conferred by testosterone therapy was reported in the current study for Factor V Leiden heterozygosity, known to be associated with osteonecrosis. 5 In this study, 5 of 16 (31%) patients who had osteonecrosis and were receiving testosterone therapy had Factor V Leiden heterozygosity compared with 4 of 48 (8%) patient control subjects who had osteonecrosis and were not receiving testosterone therapy. Testosterone therapy appears to enhance the risk of osteonecrosis conferred by Factor V Leiden heterozygosity, which is prominent among multiple thrombophilic causes of osteonecrosis.
In the current cohort, the authors measured serum estradiol levels in 5 men who were receiving testosterone therapy, examining whether and to what degree aromatization of testosterone to thrombophilic estradiol leads to high estradiol levels in patients receiving testosterone therapy. The authors found that 4 of these men had a high estradiol level (≥42.6 pg/mL). As men get older and heavier and become less physically active, aromatization of testosterone to estradiol increases. The current broad use of testosterone therapy in approximately 4,000,000 men in the United States provides a large target pool of men who are at risk for thrombosis and osteonecrosis. 36 Screening for common familial thrombophilias before the initiation of testosterone therapy could optimize estimation of the risk-benefit ratio of this therapy.
Exogenous estrogens and pregnancy promote the development of osteonecrosis, [16] [17] [18] 37 where thrombophilia induced by hyperestrogenemia is superimposed on underlying prothrombotic mutations. 19 The risk of venous thromboembolism is increased 3.4-fold in women who are heterozygous for the Factor V Leiden mutation, which increases to 25-fold when oral estrogens are given. 19 The authors emphasize that exogenous testosterone, when superimposed on underlying prothrombotic mutations or acquired thrombophilia, can also be pathoetiologic for osteonecrosis.
conclusion
When testosterone therapy is given to patients with thrombophilia, they are at increased risk for osteonecrosis. When evaluating patients with osteonecrosis, testosterone therapy, interacting with underlying thrombophilia and hypofibrinolysis, should be included with the other recognized causes of osteonecrosis.
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